AMADOR BIOSCIENCE, INC. – Trademark Portfolio
Entity Type: 03
AMADOR BIOSCIENCE, INC. has 3 U.S. trademark filings recorded with the United States Patent and Trademark Office (USPTO). Of these, 2 are successfully registered — a 67% registration rate. The portfolio includes marks such as A AMADOR BIOSCIENCE. Filings span 3 Nice Classification classes, with the highest activity in Class 42 (Computer & Scientific) and Class 41 (Education & Entertainment). This trademark owner is based in Germantown, MD.
20400 Century Blvd.
Germantown, MD 20847
Showing of trademarks Trademarks
Trademark Classifications
AMADOR BIOSCIENCE, INC.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Education; providing of training; entertainment; sporting and cultural activities
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does AMADOR BIOSCIENCE, INC. have?
AMADOR BIOSCIENCE, INC. has 3 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 abandoned.
What trademark classes does AMADOR BIOSCIENCE, INC. file in?
AMADOR BIOSCIENCE, INC. files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 41 (Education & Entertainment), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.
What are AMADOR BIOSCIENCE, INC.'s most well-known trademarks?
AMADOR BIOSCIENCE, INC.'s registered trademark portfolio includes well-known marks such as A AMADOR BIOSCIENCE. These are among 2 currently registered trademarks in the portfolio.
What is AMADOR BIOSCIENCE, INC.'s trademark registration success rate?
AMADOR BIOSCIENCE, INC. has a 67% trademark registration rate, with 2 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.